ReviewJournal of neuro-oncology2011
The biological basis for modern treatment of chordoma.
Review in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Spinal chordoma and chondrosarcoma treatment experiences - a 20-year retrospective study from databases of two medical centers.Scientific reports · 2024Article
- Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base: Evaluation of the Effectiveness of Treatment Methods (Review).Sovremennye tekhnologii v meditsine · 2023Review
- Chordoma of the Clivus with Metastasis to Femur.Asian journal of neurosurgery · 2022Article
- Article
- Personalized chordoma organoids for drug discovery studies.Science advances · 2022Article
- Bibliometric analysis of the global research trends and hotspots in chordoma from 2000 to 2020.PloS one · 2022Article
- An Integrated Management Paradigm for Skull Base Chordoma Based on Clinical and Molecular Characteristics.Journal of neurological surgery. Part B, Skull base · 2021Article
- Deficiency ofOncoTargets and therapy · 2020Article
- A historical recount of chordoma.Journal of neurosurgery. Spine · 2018Article
- Multiple primary chordomas of the lung.Respiratory medicine case reports · 2018Article
- Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2015Article
- Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR‑125a and miR‑10a expression.Molecular medicine reports · 2015Article
- OUTCOME OF CLIVAL CHORDOMAS AFTER SKULL BASE SURGERIES WITH MEAN FOLLOW-UP OF 10 YEARS.Fukushima journal of medical science · 2015Article
- Novel targeted therapies in chordoma: an update.Therapeutics and clinical risk management · 2015Review
- "En bloc" resection of sacral chordomas by combined anterior and posterior surgical approach: a monocentric retrospective review about 29 cases.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2014Article
- Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2014Article
- Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.International journal of clinical and experimental pathology · 2014Article
- Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.Neoplasia (New York, N.Y.) · 2013Article
- High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.Neoplasia (New York, N.Y.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordomas are rare malignant tumors arising in bone of the spheno-occiput, sacrum, and vertebral column which can cause neurological deficit. Current management of chordoma involves safe resection followed by radiation therapy. However, surgical resection is often subtotal and chordoma often recurs despite optimal therapy. Despite years of effort, effective adjuvant therapy for denovo, recurrent and metastatic chordoma are absent and 5-year survival is at best 65%. While no chemotherapeutic agent has been demonstrated to be effective against chordoma in vivo, a greater understanding of the genetics and molecular biology of chordoma is opening up avenues of investigation towards the rational development of targeted therapies. Although enthusiasm for the use of already established or new investigational agents will increase with greater understanding of chordoma biology, laboratory studies of these agents are important prior to incorporation into clinical human trials. The authors review the current state of knowledge regarding chordoma and offer insight into potential new therapies for this rare and challenging tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.